

Metastatic

HER2 +


3rd Line or Later

[BRS0131](#)
[Phase I/II IV Zotatifin \(eFT226\) in Selected Advanced Solid Tumor Malignancies](#)
 PI: Caswell-Jin
 Sponsor: eFFECTOR Therapeutics, Inc.

Priority 1

BRS0142
 Phase I/II Open Label Dose Escalation and Dose Expansion Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of HER2 Directed Radioligand CAM-H2 in Advanced/Metastatic HER2-Positive Breast, Gastric, & Gastro-Esophageal Junction Cancer

PI: Aparici
 Sponsor: Precirix NV



KEY

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Link Trial Posting
- Enrollment on Hold
- Extension Study
- Immunotherapy